Nymox Pharmaceutical Announces Positive Safety Monitoring Committee Results for Phase 3 BPH NX02-0020 Repeat Injection U.S. Study

HASBROUCK HEIGHTS, N.J., July 9, 2012 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) provided an update today on the Company's Phase 3 NX02-0020 repeat injection U.S. study for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The recent Safety Monitoring Committee meeting was favorable and indicated no significant safety concerns for the trial to date. Patient recruitment and trial activities for this U.S. Phase 3 Study are nearing completion at well-known urology investigative sites throughout the U.S.